Interview: GW Pharma Gears Up For Pivotal 2018

 
• By Kevin Grogan

The UK group has raised nearly $320m this week which will be used to build commercial organizations in the US and Europe ahead of potential approvals for its cannabinoid epilepsy therapy Epidiolex.

Preparation
GW gets ready in the hope its epilepsy drug gets the green light soon • Source: Shutterstock

More from Neurological

More from Therapy Areas